GlycoMimetics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephanie R. Irish CPA
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9708 Medical Center Drive Rockville MD United States of America 20850
- IPO Date
- Jan 10, 2014
- CIK
- 0001253689
- Website
- glycomimetics.com
- Similar Companies
- Business
- GlycoMimetics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of glycomimetic drugs that target carbohydrate biology to treat serious diseases. The company’s main products and services focus on developing novel therapeutics for hematologic and solid tumor cancers, as well as inflammatory and fibrotic diseases. Its core product pipeline includes uproleselan, an E-selectin antagonist designed to improve chemotherapy effectiveness in acute myeloid leukemia (AML); and other glycomimetic drug candidates targeting leukocyte trafficking and tumor microenvironment modification. GlycoMimetics operates primarily in the biotechnology industry, providing innovative therapeutic drug candidates through research, clinical development, and collaborations. Founded in 2003 and headquartered in Rockville, Maryland, GlycoMimetics serves a global market with a strategic focus on oncology and immunology therapeutic areas. Recently, the company has advanced its clinical pipeline with ongoing Phase 3 trials of uproleselan, established new partnerships to facilitate drug development and commercialization, and expanded its research collaborations to include novel glycomimetic drug candidates. The company continues to strengthen its strategic position through funded clinical trials and alliances that enhance its product offerings and accelerate drug development timelines. GlycoMimetics' product portfolio primarily includes glycomimetic antagonists of selectins (E-selectin and P-selectin), which are key mediators in cell adhesion processes implicated in cancer progression and inflammatory conditions. The company designs these small molecule drugs to inhibit cell adhesion and improve treatment outcomes when combined with chemotherapy or immunotherapy. Its efforts are directed at diseases with significant unmet medical needs such as AML, sickle cell disease, and other fibrotic and inflammatory disorders. The company is publicly traded under the ticker symbol GLYC and maintains research and development operations primarily in the United States. GlycoMimetics leverages its proprietary glycomimetic platform technology to deliver differentiated therapeutic candidates with the goal of providing improved efficacy and safety profiles compared to existing treatments. Overall, GlycoMimetics, Inc. is a specialized biotechnology firm focused on innovative glycomimetic drug discovery, clinical development, and strategic collaborations to address critical therapeutic areas in oncology and inflammatory diseases, with a strong pipeline and active clinical programs in advanced stages as of the most recent updates.
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
Crescent Biopharma Appoints David Lubner to Board of Directors
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYC
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript